1062368-26-6

Basic information

• Product Name: tert-butyl 4-(4-(3-broMopyrazolo[1,5-a]pyriMidin-6-yl)phenyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(4-(3-broMopyrazolo[1,5-a]pyriMidin-6-yl)phenyl)piperazine-1-carboxylate
• CAS NO: 1062368-26-6
• Molecular Weight: 458.358
• Mol File: 1062368-26-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-(3-broMopyrazolo[1,5-a]pyriMidin-6-yl)phenyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-(3-broMopyrazolo[1,5-a]pyriMidin-6-yl)phenyl)piperazine-1-carboxylate(1062368-26-6)
• EPA Substance Registry System: tert-butyl 4-(4-(3-broMopyrazolo[1,5-a]pyriMidin-6-yl)phenyl)piperazine-1-carboxylate(1062368-26-6)

Safety Data

• Hazardous Substances Data: 1062368-26-6(Hazardous Substances Data)

Upstream product

• 705263-10-1 6-bromo-pyrazolo[1,5-α]pyrimidine 
• 1062368-25-5 C₂₁H₂₅N₅O₂ 

Downstream Products

• 1062368-27-7 C₃₀H₃₀N₆O₂ 
• 1062368-62-0 4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride 

Relevant articles and documents

BMP INHIBITORS AND METHODS OF USE THEREOF

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.